Heligenics, a biotech company based in Las Vegas, has developed a first-of-its-kind precision genetic test that can select among drugs to treat breast cancer. The test uses Heligenics' proprietary GigaAssay technology to identify which of the 10,000 potential mutations in a cancer gene would make a patient susceptible to a drug they would want to take and which variants produced resistance to the drug. This approach will transform analysis of biopsies to create a data-driven approach to treatment. There are multiple drugs available to treat breast cancer, but most patients become drug-resistant. Although many patients eventually die from acquiring resistance to a drug, there is no systematic approach to identifying the variants that cause target-derived drug resistance. Heligenics revolutionized selection of the right drug with its first-of-its-kind genetic test for breast cancer that chooses among three FDA-approved drugs: Tykerb™, Tukysa™, and Nerlynx™. Dr. Jerome Rotter, a board member of Heligenics and Director of Translational Genomics and Population Sciences at the Lundquist Institute / Harbor-UCLA said, "This test is a great example of the future of personalized drug therapy." Heligenics is looking for commercial partners who can gain FDA